Caladrius Biosciences (NASDAQ:CLBS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm presently has a $0.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 8.65% from the stock’s […]
Related Keywords
New York , United States , Caladrius Biosciences , Caladrius Biosciences Inc , Geode Capital Management , Goldman Sachs Group Inc , Zacks Investment Research , Neostem Inc , Sigma Securities , Caladrius Biosciences Company Profile Get Rating , Barclays Plc , Millennium Management , Get Rating , Investment Research , Capital Management , Goldman Sachs Group , Biosciences Company Profile , Nasdaq Clbs , Clbs , Medical , Upgrade ,
comparemela.com © 2020. All Rights Reserved.